Tempus AI, Inc. TEM
Composite 41/100; the shares have moved about 81% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 11/100 — a strong mark against it.
Growth ranks 97/100 — a strong point in its favour. Balance-sheet strength ranks 62/100 — a moderate point in its favour.
Valuation ranks 11/100 — a strong mark against it. Quality ranks 18/100 — a strong mark against it. Momentum ranks 30/100 — a moderate mark against it.
What the company does Tempus AI operates a closed-loop healthcare technology platform integrating diagnostics, analytics, and multimodal data for clinicians and life sciences. Its core offerings include NGS testing, molecular pathology, and software applications like Lens for research and Insight for pharmacogenomics.
Key financials Tempus reports gross margin 63.4%, but operating and net margins are negative at -24.3% and -22.2%, respectively. Revenue grew 36.1% year-over-year, while EPS growth is flat. ROE is -81.6%, ROA -9.1%, and ROCE -13.4%, reflecting high capital intensity and early-stage scaling losses.
Stock health The stock is down -24.02% over 12 months and -57.54% from its 52-week high, with RSI(14) at 38.60 indicating oversold conditions. Sideravia scores the stock Poor quality (42.0/100), citing weak momentum (25.3) despite fair valuation (61.3).
Price vs fair value The stock trades at a discount of 51.80% versus the analyst 12-month target of 67.23. - Q2 revenue surged 22% to $382M, beating estimates (GuruFocus.com). - Tempus beat revenue estimates but reported a Q2 loss (Zacks). - CEO sold 250,000 shares, raising liquidity concerns (Motley Fool). - Cathie Wood’s Ark maintains a bullish median target of $243.81 (Motley Fool).
Looking forward Analysts expect continued revenue growth, but profitability remains uncertain amid high R&D and scaling costs. Momentum metrics suggest potential near-term volatility despite long-term opportunity in precision medicine.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.